Yttrium 90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy for B-Cell Non-Hodgkin's Lymphoma: Letter from the Editors

Leonard M. Freeman, M. Donald Blaufox

Research output: Contribution to journal › Editorial › peer-review

Fingerprint

Dive into the research topics of 'Yttrium 90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy for B-Cell Non-Hodgkin's Lymphoma: Letter from the Editors'. Together they form a unique fingerprint.